< Back to latest news & events

News

G3/19: A further Referral to the Enlarged Board of Appeal on Plants Produced by Essentially Biological Processes

June 2019

In decision T1063/18, a EPO Technical Board of Appeal created controversy in ruling that the jurisprudence of the Enlarged Board of Appeal took precedence over Rule 28(2) of the EPC. The Board held that decisions G2/12 and G2/13 should be followed in preference to the rule, thus allowing claims to plants produced by essentially biological processes.

T1063/18 created uncertainty as to how the EPO would deal with this conflict; were examiners to follow the rules or the Board’s precedent? Many expected that the EPO would have to take action to clarify the legal situation, and many hoped that there would be a referral to the Enlarged Board of Appeal. This has now happened.

To give a little more background, we first reported back in December 2018 on T1063/18 that the Board considered that controversial R.28(2) EPC is in conflict with A.53(b) EPC, as interpreted in both the Enlarged Board decisions G2/12 and G2/13 (“broccoli II” and “tomatoes II”), and was therefore improper. As a result of this, the Board held that R.28(2) EPC should be ignored, and that plants produced by essentially biological processes are indeed patentable.

In the EPO Official Journal for May 20191, it was announced that the President of the EPO has now referred questions regarding this point of law to the Enlarged Board under case number G3/19. The questions referred by the President are as follows:

  1. Having regard to Article 164(2) EPC, can the meaning and scope of Article 53 EPC be clarified in the Implementing Regulations to the EPC without this clarification being a priori limited by the interpretation of said article given in an earlier decision of the boards of appeal or the Enlarged Board of Appeal?
  2. If the answer to question 1 is yes, is the exclusion from patentability of plants and animals exclusively obtained by means of an essentially biological process pursuant to Rule 28(2) EPC in conformity with Article 53(b) EPC which neither explicitly excludes nor explicitly allows said subject-matter?

There is some disagreement as to whether the referral is admissible, given that two Enlarged Board of Appeal decisions have already dealt with the patentability of plants and animals exclusively obtained by means of an essentially biological process; G2/12 and G2/13. Furthermore, there do not appear to be conflicting T decisions on this matter. However, in the grounds for referral2, the President argues that there is different case law on the way the existence of a conflict between Article 53 EPC and a Rule which clarifies its meaning and scope is examined under Article 164(2) EPC. Thus, the questions are admissible. The President further argues that the purpose of the President’s right of referral under Article 112(1)(b) EPC is to establish uniformity of law and legal certainty within the European patent system, and that the point of law raised in T1063/18 is of fundamental importance.  We concur that clarity on this area is certainly needed.

It is not yet known whether the Enlarged Board of Appeal will decide on this referral or whether they will deem it inadmissible. However, the EPO has announced3 that any cases whose outcome depends entirely on the Enlarged Board decision will be stayed pending the outcome.

The deadline for filing third party statements is 1st October 2019. We will provide further updates as and when they are announced.

[1] – https://epo.org/law-practice/legal-texts/official-journal/2019/05/a52.html

[2] – https://documents.epo.org/projects/babylon/eponet.nsf/0/4F62ECCAF1B2F2F5C12584020026796E/$File/Referral%20under%20Art.%20112(1)(b)%20EPC-%20G%203-19.pdf

[3] – https://www.epo.org/law-practice/legal-texts/official-journal/information-epo/archive/20190410.html

This update was prepared by HGF Senior Patent Attorney Ellie Purnell.  If you would like further advice on this or any other matter, please contact Ellie Purnell. Alternatively, you can contact your usual HGF representative or visit our Contact page to get in touch with your nearest HGF office.

Latest updates

HGF Ranked #1 in the UK for Trade Mark Portfolios in the 2025 Trade Mark Filing Trends Report by Clarivate.

HGF has achieved the #1 ranking for the UK for trade mark portfolios in the newly released 2025 Trade mark Filing Trends report by Clarivate, recognising the firm as a …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

IP Ingredients: Summer Case Law Review 2025

As the British summer swings once again between sunburn and showers, it’s a great time to take stock of what the first half of the year has delivered by way …

Read article

Celebrating exam success at HGF!

We are once again delighted to share that our colleagues have achieved success in their recent exams! Their dedication, perseverance, and commitment to professional development have paid off, and we …

Read article

Is the Supreme Court denial in Thatcher’s case a fatal blow against lookalikes?

The dispute between Thatcher’s Cider Company and Aldi Stores Limited has been long running and has sparked legal controversy along the way. On 4th June 2025 the Supreme denied Aldi …

Read article

HGF ranked among Europe’s top patent firms in IP STARS Patent Rankings 2025

HGF has once again made a bold mark in the latest Managing IP Stars 2025 firm rankings, with top-tier recognition across multiple jurisdictions for our patent expertise. This year’s results …

Read article

The Enlarged Board of Appeal has today issued its decision in seminal case G1/24

G1/24, described as one of the most important cases in decades, relates to how claims of patents are to be interpreted by the Boards of Appeal and, by extension, all …

Read article